

Scientific Productivity

The output of scientific publications is one of the main criteria through which the excellence of research centres can be determined. To assess the CNIO in the national and international context, we have conducted a benchmark study of our publication record and compared it to that of other Spanish institutions (see Table I) as well as representative international research centres.

For the analysis of publications by Spanish institutions, we have considered the articles published from 2007 to 2010 in journals listed in Thomson Reuters' ISI Web of Knowledge database of scientific publications in all fields of knowledge. The analysis of international institutions was based on publications published from 2007 to 2009.

As far as the productivity of Spanish institutions is concerned, we only considered those articles whose senior/corresponding author is affiliated with a Spanish institution, including all universities, research centres and hospitals. Publications of collaborative studies in which the senior author is from a different country were not considered.

Similarly, articles were counted as having been generated by a given research centre only if the senior/corresponding author was affiliated with this centre. In those cases where a publication had more than one corresponding author, the affiliation of the last author of the publication was used for the classification.

Competitiveness of the CNIO within Spain

During the period 2007-2010, a total of over 108,000 scientific articles (figures for 2010 are not definitive) were published by universities, hospitals and research centres in Spain in all fields of scientific research. The CNIO generated 479 of these articles, 119 in 2007, 123 in 2008, 120 in 2009 and 117 in 2010. This represents 0.4% of the total scientific articles published by Spanish institutions during this period, without taking into consideration their quality based on their impact factor (IF).

However, when the IF of the publications was considered, the contribution of the CNIO to the scientific output in Spain increased dramatically. For instance, when we analysed publications in the very top tier journals (those with an $IF \geq 15$), the CNIO's share of the national scientific output during the period 2007-2010 increased to 8.6% (55 out of a total of 640 publications in this category) (Table I).

In other words, whereas the percentage of all Spanish publications appearing in the top journals (those with an $IF \geq 15$) was 0.6% (640 out of 108,000), the percentage of the

CNIO publications published in this selected category was 11.5% (55 out of 479), almost 20 times higher than the average.

When the publication record of the CNIO research groups was compared to those of other Spanish institutions, the outcome was also quite dramatic. As illustrated in Table I, the number of CNIO publications in the high impact factor category represented almost 39% of that of the entire Spanish Research Council (CSIC), including the joint CSIC-University Centres. Likewise, when we compared our performance in this category with that of the entire Spanish University System that includes more than 80 universities in all the fields of knowledge, or with that of the 175 Spanish University Hospitals, it turned out that our output represented 36% and 33% of their productivity levels, respectively (Table I).

Table I. Analysis of publications with an IF \geq 15 in 2007-2010*

	2007	2008	2009	2010	2007-2010	%*
CNIO	19	15	11	10	55	8.59
CSIC (including joint CSIC-University Centres)	37	29	46	31	143	22.34
Hospitals	39	33	46	47	165	25.78
Universities	23	37	44	49	153	23.91
Others	12	31	39	42	124	19.38
Total	130	145	186	179	640	100

* Values represent number of publications in all the fields of knowledge, as included in the Thomson Reuters' ISI Web of Knowledge database as of 16th March 2010. Impact factors correspond to the year of publication, except for the 2010 publications, for which the 2009 IFs have been used.

Competitiveness of the CNIO at International Level

In the international context, the CNIO's competitiveness is clearly shown in a recent publication by the SCImago Institutions Ranking (SIR, www.scimagoir.com). Here, the CNIO ranked 13th in the research institutions working in the field of life sciences and biomedicine worldwide, when considering the parameter of "High Quality Publications". This criterion is defined as "the ratio of publications that an institution publishes in the most influential scholarly journals of the world". Journals considered for this indicator are those ranked in the first quartile (25%) in their respective categories as ordered by the SCImago Journal Rank SJR indicator. According to this criterion, the CNIO's output in this key indicator was 88.18, whereas that of the Whitehead Institute at MIT, which tops the list, was 93.75.

Being placed as the 13th best research institution in the world in the broad field of life sciences is already quite an accomplishment for our relatively young research centre. Since we are not however completely familiar with the criteria used by the SIR to define quality, we decided to extend this analysis using our own benchmarking criteria. Specifically, we compared the number of publications in high impact factor journals (IF>15) normalised by the number of independent research groups housed in each of the institutions topping the SIR ranking. To avoid giving equal value to our own publications versus collaborations, each publication was only counted once and ascribed to the institution housing the corresponding author.

The results of this benchmarking analysis showed that the CNIO ranks second in the world with its 45 publications and 29 research groups, yielding a ratio of 1.55 publications per research group. Ahead of the CNIO was the Whitehead Institute, with an impressive ratio of 3.74 publications per research group (71 publications and 19 research groups). Other prestigious research institutions including those appearing ahead of the CNIO in the SIR ranking had slightly lower ratios than the CNIO. Among these institutions, nine of them had a ratio >1.0 publications per research group, including the Rockefeller University, European Molecular Biology Laboratory (EMBL), Fred Hutchinson Cancer Research Centre, Salk Institute, Sanger Centre, Vienna's Institute of Molecular Pathology, Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center and the Cold Spring Harbor Laboratory.

Since these data were obtained from the websites of these institutions, they have to be considered with some caution, as it is possible that small errors may affect the results. Moreover, the small differences observed among the research institutions in this list of top research centres are not meaningful, and they should not be used by any means to establish any type of formal "rankings". Yet, our benchmark analysis represents an objective demonstration of the fact that, despite being a relatively young centre, **the CNIO is already highly competitive, ranking among the very top research institutions worldwide in the field of Life Sciences.**

CNIO Articles 2010

Below is the list of 107 scientific articles published by CNIO scientists as senior/corresponding author, ranked by their corresponding impact factor; the average impact factor (IF) of these articles was 8.45. Additionally, 8 articles were published in journals which do not have an impact factor allocated.

IF: 47.05

Hidalgo M (2010). Pancreatic cancer. *New Engl J Med* 362, 1605-1617.

IF: 34.48

Serrano M (2010). Cancer: a lower bar for senescence. *Nature* 464, 363-364.

IF: 29.54

Herranz D, Serrano M (2010). SIRT1: recent lessons from mouse models. *Nat Rev Cancer* 10, 819-823.

IF: 29.54

Collado M, Serrano M (2010). Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer* 10, 51-57.

IF: 29.49

Leitner F, Chatr-aryamontri A, Mardis SA, Ceol A, Krallinger M, Licata L, Hirschman L, Cesareni G, Valencia A (2010). The FEBS Letters/BioCreative II.5 experiment: making biological information accessible. *Nat Biotechnol* 28, 897-899.

IF: 25.29

Manchado E, Guillaumot M, de Cárcer G, Eguren M, Trickey M, García-Higuera I, Moreno S, Yamano H, Cañamero M, Malumbres M (2010). Targeting mitotic exit leads to tumor regression *in vivo*: modulation by Cdk1, Mastl, and the PP2A/B55 α , δ Phosphatase. *Cancer Cell* 18, 641-654.

IF: 25.29

Collado M, Serrano M (2010). The TRIP from ULF to ARF. *Cancer Cell* 17, 317-318.

IF: 25.29

Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M (2010). A Synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. *Cancer Cell* 18, 63-73.

IF: 20.59

Belver L, de Yébenes VG, Ramiro AR (2010). MicroRNAs prevent the generation of autoreactive antibodies. *Immunity* 33, 713-722.

IF: 19.53

Martinez P, Thanasoula M, Carlos Ana R, Gómez-Lopez G, Tejera AM, Schoeftner S, Dominguez O, Pisano DG, Tarsounas M, Blasco MA (2010). Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. *Nat Cell Biol* 12, 768-780.

IF: 14.61

Rivera T, Losada A (2010). Recycling cohesin rings by deacetylation. *Mol Cell* 39, 657-659.

IF: 14.61

Santamaria PG, Nebreda AR (2010). Deconstructing ERK signaling in tumorigenesis. *Mol Cell* 38, 3-5.

IF: 14.47

Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Suárez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Krijff P, Lenders JW, Cremers CW, Devilee P, Dinjens WN, de Krijger RR, Robledo M (2010). *SDHAF2* mutations in familial and sporadic paraganglioma and pheochromocytoma. *Lancet Oncol* 11, 366-372.

IF: 14.15

Carretero M, Remeseiro S, Losada A (2010). Cohesin ties up the genome. *Curr Opin Cell Biol* 22, 781-787.

IF: 13.36

Portela M, Casas-Tinto S, Rhiner C, López-Gay JM, Domínguez O, Soldini D, Moreno E (2010). *Drosophila* SPARC is a self-protective signal expressed by loser cells during cell competition. *Dev Cell* 19, 562-573.

IF: 13.36

Rhiner C, López-Gay J, Soldini D, Casas-Tinto S, Martín F, Lombardía L, Moreno E (2010). Flower forms an extracellular code that reveals the fitness of a cell to its neighbors in *Drosophila*. *Dev Cell* 18, 985-998.

IF: 13.36

Tejera AM, Stagno d'Alcontres M, Thanasoula M, Marion RM, Martínez P, Liao C, Flores JM, Tarsounas M, Blasco MA (2010). TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. *Dev Cell* 18, 775-789.

IF: 12.07

Guillou E, Ibarra A, Coulon V, Casado-Vela J, Rico D, Casal I, Schwob E, Losada A, Méndez J (2010). Cohesin organizes chromatin loops at DNA replication factories. *Genes Dev* 24, 2812-2822.

IF: 10.99

Ruiz EJ, Vilar M, Nebreda AR (2010). A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. *Curr Biol* 20, 717-723.

IF: 10.55

Martin-Perez D, Piris MA, Sanchez-Beato M (2010). Polycomb proteins in hematologic malignancies. *Blood* 116, 5465-5475.

IF: 10.55

Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. (2010). A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. *Blood* 116, e12-e17.

IF: 9.57

McNees CJ, Tejera AM, Martínez P, Murga M, Mulero F, Fernandez-Capetillo O, Blasco MA (2010). ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase. *J Cell Biol* 188, 639-652.

IF: 9.57

Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA (2010). SIRT1 contributes to telomere maintenance and augments global homologous recombination. *J Cell Biol* 191, 1299-1313.

IF: 9.57

Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M, Wagner EF (2010). Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. *J Cell Biol* 190, 1093-1106.

IF: 9.43

Hafner C, Toll A, Fernández-Casado A, Earl J, Marqués M, Acquadro F, Méndez-Pertuz M, Urioste M, Malats N, E Burns JE, Knowles M, Cigudosa JC, Hartmann A, Vogt T, Landthaler M, M. Pujol RM, Real FX (2010). Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. *Proc Natl Acad Sci USA* 107, 20780-20785.

IF: 9.43

Rausell A, Juan D, Pazos F, Valencia A (2010). Protein interactions and ligand binding: from protein subfamilies to functional specificity. *Proc Natl Acad Sci USA* 107, 1995-2000.

IF: 8.99

Marión RM, Blasco MA (2010). Telomere rejuvenation during nuclear reprogramming. *Curr Opin Genet Dev* 20, 190-196.

IF: 8.99

Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E,

Barbacid M (2010). Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. *EMBO J* 29, 1091-1104.

IF: 8.99

Cuadrado A, Corrado N, Perdiguero E, Lafarga V, Muñoz-Canoves P, Nebreda AR (2010). Essential role of p18Hamlet/SRCAP-mediated histone H2A.Z chromatin incorporation in muscle differentiation. *EMBO J* 29, 2014-2025.

IF: 8.79

Ruppen I, Grau L, Orenes-Piñero E, Ashman K, Gil M, Algaba F, Bellmunt J, Sánchez-Carbayo M (2010). Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor *KiSS-1* gene. *Mol Cell Proteomics* 9, 2276-2291.

IF: 8.30

Herreros B, Rodríguez-Pinilla SM, Pajares R, Martínez-González MA, Ramos R, Muñoz I, Montes-Moreno S, Lozano M, Sánchez-Verde L, Roncador G, Sánchez-Beato M, de Otazu RD, Pérez-Guillermo M, Mestre MJ, Bellas C, Piris MA (2010). Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place. *Leukemia* 24, 872-876.

IF: 8.30

Di Lisio L, Gómez-López G, Sánchez-Beato M, Gómez-Abad C, Rodríguez ME, Villuendas R, Ferreira BI, Carro A, Rico D, Mollejo M, Martínez MA, Menárguez J, Díaz-Alderete A, Gil J, Cigudosa JC, Pisano DG, Piris MA, Martínez N (2010). Mantle cell lymphoma: transcriptional regulation by microRNAs. *Leukemia* 24, 1335-1342.

IF: 8.24

Meixner A, Karreth F, Kenner L, Penninger JM, Wagner EF (2010). Jun and JunD-dependent functions in cell proliferation and stress response. *Cell Death Differ* 17, 1409-1419.

IF: 8.11

Wagner EF (2010). Bone Development and Inflammatory Disease is regulated by AP-1 (Fos/Jun). *Ann Rheum Dis* 69, i86-i88.

IF: 7.67

Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N; for the EPICURO/Spanish Bladder Cancer Study investigators (2010). Genetic susceptibility to distinct bladder cancer subphenotypes. *Eur Urol* 57, 283-292.

IF: 7.55

Martínez P, Blasco MA (2010). Role of shelterin in cancer and aging. *Aging Cell* 9, 653-666.

IF: 7.54

Escobar B, de Carcer G, Fernandez-Miranda G, Cascon A, Bravo-Cordero J, Montoya M, Robledo M, Canamero

M, Malumbres M (2010). Brick1 is an essential regulator of actin cytoskeleton required for embryonic development and cell transformation. *Cancer Res* 70, 9349-9359.

IF: 7.48

Carro A, Rico D, Rueda OM, Díaz-Uriarte R, Pisano DG (2010). waviCGH: a web application for the analysis and visualization of genomic copy number alterations. *Nucleic Acids Res* 38, w182-w187.

IF: 7.13

Varela E, Blasco MA (2010). 2009 nobel prize in physiology or medicine: telomeres and telomerase. *Oncogene* 29, 1561-1565.

IF: 7.13

Zanella F, Renner O, García B, Callejas S, Dopazo A, Peregrina S, Carnero A, Link W (2010). Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. *Oncogene* 29, 2973-2982.

IF: 6.92

Hermann PC, Bhaskar S, Cioffi M, Heeschen C (2010). Cancer stem cells in solid tumors. *Semin Cancer Biol* 20, 77-84.

IF: 6.91

Zanella F, Lorens JB, Link W (2010). High content screening: seeing is believing. *Trends Biotechnol* 28, 237-245.

IF: 6.91

Baudot A, de la Torre V, Valencia A (2010). Mutated genes, pathways and processes in tumours. *EMBO Rep* 11, 805-810.

IF: 6.91

Fernandez-Capetillo O. (2010). Intrauterine programming of ageing. *EMBO Rep* 11, 32-36.

IF: 6.89

Schiavi F, Milne RL, Anda E, Blay P, Castellano M, Opocher G, Robledo M, Cascón A (2010). Are we overestimating the penetrance of mutations in *SDHB*? *Hum Mutat* 31, 761-762.

IF: 6.83

Alonso-Curbelo D, Soengas MS (2010). Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. *Autophagy* 6, 148-150.

IF: 6.75

Riveiro-Falkenbach E, Soengas MS (2010). Control of tumorigenesis and chemoresistance by the DEK oncogene. *Clin Cancer Res* 16, 2932-2938.

IF: 6.42

Kanellis G, Mollejo M, Montes-Moreno S, Rodríguez-Pinilla SM, Cigudosa JC, Algara P, Montalbán C, Matutes

E, Wotherspoon A, Piris MA (2010). Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. *Haematologica* 95, 1122-1129.

IF: 6.42

Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, de La Cueva P, Rodríguez ME, Herreros B, Martín-Pérez D, Longo MI, Herrera M, Piris MA, Ortiz-Romero PL (2010). Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. *Haematologica* 95, 613-621.

IF: 6.42

Montes-Moreno S, Gonzalez-Medina AR, Rodríguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G, Mollejo M, García JF, Menárguez J, Montalbán C, Ruiz-Marcellan MC, Conde E, Piris MA (2010). Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. *Haematologica* 95, 1342-1349.

IF: 6.34

Schoeftner S, Blasco MA (2010). Chromatin regulation and non-coding RNAs at mammalian telomeres. *Semin Cell Dev Biol* 21, 186-193.

IF: 6.14

Fernández-Miranda G, de Castro IP, Carmena M, Aguirre-Portolés C, Ruchaud S, Fant X, Montoya G, Earnshaw WC, Malumbres M (2010). SUMOylation modulates the function of Aurora-B kinase. *J Cell Sci* 123, 2823-2833.

IF: 6.14

Mourón S, de Cárcer G, Seco E, Fernández-Miranda G, Malumbres M, Nebreda AR (2010). RINGO C is required to sustain the spindle-assembly checkpoint. *J Cell Sci* 123, 2586-2595.

IF: 6.09

Marcaida MJ, Muñoz IG, Blanco FJ, Prieto J, Montoya G (2010). Homing endonucleases: from basics to therapeutic applications. *Cell Mol Life Sci* 67, 727-748.

IF: 6.06

Bueno MJ, Gómez de Cedrón M, Laresgoiti U, Fernández-Piqueras J, Zubiaga AM, Malumbres M (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. *Mol Cell Biol* 30, 2983-2995.

IF: 5.67

Martín-Pérez D, Sánchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, Martínez N, Alves J, Piris MA, Sánchez-Beato M (2010). Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. *Am J Pathol* 177, 930-942.

IF: 5.54

Wozniak MB, Piris MA (2010). Cutaneous T-cell lymphoma: two faces of the same coin. *J Invest Dermatol* 130, 348-351.

IF: 5.26

López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas A, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Díez-Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascón A (2010). Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. *Mol Endocrinol* 24, 2382-2391.

IF: 5.15

Cuadrado A, Nebreda AR (2010). Mechanisms and functions of p38 MAPK signalling. *Biochem J* 429, 2014-2025.

IF: 5.13

Orenes E, Barderas R, Rico D, Casal I, González-Pisano D, Navajo J, Algaba F, Piulats JM, Sanchez-Carbayo M (2010). Serum and tissue profiling in bladder cancer combining protein and tissue arrays. *J Proteome Res* 9, 164-173.

IF: 5.13

Zanella F, Link W, Carnero A (2010). Understanding FOXO, new views on old transcription factors. *Curr Cancer Drug Targets* 10, 135-146.

IF: 4.95

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M (2010). A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. *Mol Cancer Ther* 9, 2582-2592.

IF: 4.93

Glaab E, Baudot A, Krasnogor N, Valencia A (2010). TopoGSA: network topological gene set analysis. *Bioinformatics* 26, 1271-1272.

IF: 4.80

Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, Reymundo I, Rabal O, Salgado A, Corrión A, Fominaya J, Pastor J, Bischoff JR (2010). Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. *J Med Chem* 53, 6618-6628.

IF: 4.80

Sutto L, D'Abramo M, Gervasio FL (2010). Comparing the efficiency of biased and unbiased molecular dynamics in reconstructing the free energy landscape of Met-enkephalin. *J Chem Theory Comput* 6, 3640-3646.

IF: 4.70

Milne RL, Osorio A, Ramón Y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C,

Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J (2010). Parity and the risk of breast and ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res Treat* 119, 221-232.

IF: 4.43

Luque-García JL, Martínez-Torrecuadrada JL, Epifano C, Cañamero M, Babel I, Casal JI (2010). Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. *Proteomics* 10, 940-952.

IF: 4.41

Carnero A (2010). The PKB/AKT pathway in cancer. *Curr Pharm Design* 16, 34-44.

IF: 4.35

Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. *Br J Cancer* 103, 649-655.

IF: 4.35

Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A (2010). Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. *PLoS One* 5, e9305.

IF: 4.35

Tendulkar AV, Krallinger M, de la Torre V, López G, Wangikar PP, Valencia A (2010). FragKB: structural and literature annotation resource of conserved peptide fragments and residues. *PLoS One* 5, e9679.

IF: 4.35

García-Jiménez B, Juan D, Ezkurdia I, Andrés-León E, Valencia A (2010). Inference of functional relations in predicted protein networks with a machine learning approach. *PLoS One* 5, e9969.

IF: 4.35

Fernandez-Marcos PJ, Pantoja C, Gonzalez-Rodriguez A, Martin N, Flores JM, Valverde AM, Hara E, Serrano M (2010). Normal proliferation and tumorigenesis but impaired pancreatic function in mice lacking the cell cycle regulator Sei1. *PLoS One* 5, e8744.

IF: 4.35

Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, Prósper F, Martín-Subero JI, Maiques A, Acquadro F, Rodriguez Perales S, Calasanz MJ, Roman-Gómez J, Siebert R, Mulloy JC, Cervera J, Sanz MA, Esteller M, Cigudosa JC (2010). DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. *PLoS One* 5, e12197.

IF: 4.35

Rosa-Rosa JM, Gracia-Aznárez FJ, Hodges E, Pita G, Rooks M, Xuan Z, Bhattacharjee A, Brizuela L, Silva JM,

Hannon GJ, Benitez J (2010). Deep sequencing of target linkage assay-identified regions in familial breast cancer: methods, analysis pipeline and troubleshooting. *PLoS One* 5, e9976.

IF: 4.31

Amaral AFS, Cantor KP, Silverman DT, Malats N (2010). Selenium and bladder cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 19, 2407-2415.

IF: 4.28

Leskelä S, Leandro-García LJ, Mendiola M, Barrioso J, Inglada-Perez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez Antona C (2010). miR-200 family controls β -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. *Endocr-Relat Cancer* 18, 85-95.

IF: 4.28

Rodríguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-García L, Lopez-Jimenez E, Letón R, Cascón A, Lerma E, Martín MC, Carralero MC, Maurício D, Cigudosa J, Matias-Guiu X, Robledo M (2010). Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. *Endocr-Relat Cancer* 17, 7-16.

IF: 4.28

Landa I, Montero-Conde C, Malanga D, De Gisi S, Pita G, Leandro-García LJ, Inglada-Pérez L, Letón R, De Marco C, Rodríguez-Antona C, Viglietto G, Robledo M (2010). Allelic variant at -79 (C>T) in *CDKN1B* (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. *Endocr-Relat Cancer* 17, 317-328.

IF: 4.20

López-Contreras AJ, Fernandez-Capetillo O (2010). The ATR barrier to replication-born DNA damage. *DNA Repair* 9, 1249-1255.

IF: 4.09

Méndez J (2010). Cyclin E goes nuts: a cell cycle regulator affects male fertility. *Cell Cycle* 9, 4782-4787.

IF: 4.09

Llanos S, Serrano M (2010). Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. *Cell Cycle* 9, 4005-4012.

IF: 4.09

Serrano M (2010). Shifting senescence into quiescence by dialling up p53. *Cell Cycle* 9, 4256-4257.

IF: 4.06

Rodríguez-Pinilla SM, Barrionuevo C, García J, Mart Nez MT, Pajares R, Montes-Moreno S, Casavilca S, Montes J, Bravo F, Zaharia M, Zevallos-Giampietri E, Sanchez L, Piris MA (2010). EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from Peru in children and young adults. *Am J Surg Pathol* 34, 1773-1782.

IF: 4.02

Alvarez-Múgica M, Cebrían V, Fernández-Gómez JM, Fresno F, Escaf S, Sánchez-Carbayo M (2010). Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. *J Urology* 184, 1507-1513.

IF: 3.89

Rodríguez-Antona C (2010). Pharmacogenomics of paclitaxel. *Pharmacogenomics* 11, 621-623.

IF: 3.86

Rabal O, Link W, G Serelbe B, Bischoff JR, Oyarzabal J (2010). An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. *Mol Biosyst* 6, 711-720.

IF: 3.85

Montes-Moreno S, Castro Y, Rodríguez-Pinilla SM, García JF, Mollejo M, Castillo ME, Bas-Vernal A, Barrionuevo-Cornejo C, Sanchez-Verde L, Menarguez J, Cigudosa JC, Piris MA (2010). Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. *Histopathology* 56, 658-662.

IF: 3.85

Cano I, Lozano M, Rodríguez A, Mate A, Adrados M, López Mdel M, Carro R, Montes-Moreno S (2010). Nodular lymphocyte-predominant Hodgkin lymphoma and T cell histiocyte-rich large B cell lymphoma: diagnosis in two monozygotic twins. *Histopathology* 57, 159-162.

IF: 3.85

Montes-Moreno S, García OA, Santiago-Ruiz G, Ferreira JA, García JF, Pinilla MA (2010). Primary luetic lymphadenopathy simulating sarcoma-like inflammatory pseudotumour of the lymph node. *Histopathology* 56, 656-658.

IF: 3.76

Zajac M, Gomez G, Benítez J, Martínez-Delgado B (2010). Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. *BMC Genomics* 3, 44.

IF: 3.74

Mueller MT, Hermann PC, Heeschen C (2010). Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. *Front Biosci* 2, 602-613.

IF: 3.54

Flores I, Blasco MA (2010). The role of telomeres and telomerase in stem cell aging. *FEBS Lett* 584, 3826-3830.

IF: 3.54

Lemaire M, Ducommun B, Nebreda AR (2010). UV-induced downregulation of the CDC25B protein in human cells. *FEBS Lett* 584, 1199-1204.

IF: 3.54

Leitner F, Krallinger M, Cesareni G, Valencia A (2010). The FEBS Letters SDA corpus: a collection of protein interaction articles with high quality annotations for the BioCreative II.5 online challenge and the text mining community. *FEBS Lett* 584, 4129-4130.

IF: 3.47

Fidelak J, Juraszek J, Branduardi D, Bianciotto M, Gervasio FL (2010). Free-Energy-Based Methods for Binding Profile Determination in a Congeneric Series of CDK2 Inhibitors. *J Phys Chem B* 114, 9516-9524.

IF: 3.43

Glaab E, Baudot A, Krasnogor N, Valencia A (2010). Extending pathways and processes using molecular interaction networks to analyse cancer genome data. *BMC Bioinformatics* 11, 579.

IF: 3.41

Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, Sanchez-Carbayo M (2010). Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. *J Transl Med* 8, 86.

IF: 3.38

Manchado E, Eguren M, Malumbres M (2010). The anaphase promoting complex (APC/C): cell cycle dependent and independent functions. *Biochem Soc Trans* 38, 65-71.

IF: 3.24

Ibarrola-Villava M, Fernandez LP, Pita G, Bravo J, Floristan U, Sendagorta E, Feito M, Avilés JA, Martín-Gonzalez M, Lázaro P, Benítez J, Ribas G (2010). Genetic analysis of three important genes in pigmentation and melanoma susceptibility: *CDKN2A*, *MC1R* and *HERC2/OCA2*. *Exp Dermatol* 19, 836-844.

IF: 3.08

Tress ML, Valencia A (2010). Predicted residue-residue contacts can help the scoring of 3D models. *Proteins* 78, 1980-1981.

IF: 2.66

Lonardo E, Hermann PC, Heeschen C. (2010). Pancreatic cancer stem cells - update and future perspectives. *Mol Oncol* 4, 431-442.

IF: 2.25

Leitner F, Mardis SA, Krallinger M, Cesareni G, Hirschman LA, Valencia A (2010). An overview of BioCreative II.5. *IEEE/ACM Trans Comput Biol Bioinform* 7, 385-399.

IF: 1.94

Sanchez-Carbayo M (2010). Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. *Tumor Biol* 31, 103-112.

IF: 1.94

Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Córdón-Cardo C, Sánchez-Carbayo M (2010). Galectin-3 expression is associated with bladder cancer progression and clinical outcome. *Tumor Biol* 31, 277-285.

IF: 1.61

Salgado A, Varela C, García Collazo AM, Pevarello P (2010). Differentiation between [1,2,4]triazolo[1,5-a]pyrimidine and [1,2,4]triazolo[4,3-a]pyrimidine regioisomers by 1H-15N HMBC experiments. *Magn Reson Chem* 48, 614-622.

IF: 0.55

Culurgioni S, Muñoz IG, Palacios A, Redondo P, Blanco FJ, Montoya G (2010). Crystallization and preliminary X-ray diffraction analysis of the dimerization domain of the tumour suppressor ING4. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 66, 567-570.

The following articles were published in journals that have not been allocated an impact factor.

Herranz D, Serrano M (2010). Impact of Sirt1 on mammalian aging. *Aging (Albany)* 2, 315-316.

Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M, Rodríguez-Antona C (2010). Tumoral and tissue-specific expression of the major human beta-tubulin isoforms. *Cytoskeleton* 67, 214-223.

Collado M (2010). Exploring a 'pro-senescence' approach for prostate cancer therapy by targeting PTEN. *Future Oncol* 6, 687-689.

de Yébenes VG, Ramiro AR (2010). MicroRNA activity in B lymphocytes. *Methods Mol Biol* 667, 177-192.

Krallinger M, Leitner F, Valencia A (2010). Analysis of biological processes and diseases using text mining approaches. *Methods Mol Biol* 593, 341-382.

Herranz D, Muñoz-Martin M, Cañamero M, Mulero F, Martínez-Pastor B, Fernández-Capetillo O, Serrano M (2010). Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. *Nat Communications* 1, 1-8.

López de Silanes I, Stagno d'Alcontres M, Blasco MA (2010). TERRA transcripts are bound by a complex array of RNA-binding proteins. *Nat Communications* 1, 1-9.

Wagner EF, Schonhaler HB, Guinea-Viniestra J, Tschachler E (2010). Psoriasis: what we have learned from mouse models. *Nat Rev Rheumatol* 6, 704-714.

Collaborations

In 2010, CNIO scientists co-authored 104 articles from collaborative work carried out with other institutions (principal or senior/corresponding author not from CNIO). Of those, 69 articles were in collaboration with foreign institutions; with an average IF of 9.23. The other 35 articles were collaborations with Spanish institutions; the average IF of these articles was 6.00. Additionally, 6 articles were published in peer-reviewed journals which do not have an IF allocated.

Collaborations with foreign institutions

IF: 42.20

Frame MC, Patel H, Serrels B, Lietha D, Eck MJ (2010). The FERM domain: organizing the structure and function of FAK. *Nat Rev Mol Cell Biol* 11, 802-814.

IF: 34.48

International Cancer Genome Consortium. (2010). International network of cancer genome projects. *Nature* 464, 993-998.

IF: 34.28

Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajcinovic M, Sinnett D, Healy J, Gonzalez Neira A, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS (2010). Variation in *CDKN2A* at 9p21.3 influences childhood acute lymphoblastic leukemia risk. *Nat Genet* 42, 492-494.

IF: 34.28

Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghousaini M, Barrowdale D; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P; GEMO Study Collaborators, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gómez García EB; HEBON, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Górski B, Cybulski C, Spurdle AB, Holland H; kConFab, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C; SWE-BRCA, Loman N, Harbst K, Rantalala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM,

Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI; MOD SQUAD, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H; GENICA, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rüdiger T, Försti A, Winqvist R, Pyrkäs K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ (2010). A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 42, 885-892.

IF: 34.28

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeny LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjønneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurdau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ (2010). A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nat Genet* 42, 978-984.

IF: 31.15

Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A (2010). 53BP1 inhibits homologous recombination in *Brca1*-deficient cells by blocking resection of DNA breaks. *Cell* 141, 243-254.

IF: 29.75

Baur JA, Chen D, Chini EN, Chua K, Cohen HY, de Cabo R, Deng C, Dimmeler S, Gius D, Guarente LP, Helfand SL, Imai S, Itoh H, Kadowaki T, Koya D, Leeuwenburgh C, McBurney M, Nabeshima Y, Neri C, Oberdoerffer P, Pestell RG, Rogina B, Sadoshima J, Sartorelli V, Serrano M, Sinclair DA, Steegborn C, Tatar M, Tissenbaum HA, Tong Q, Tsubota K, Vaquero A, Verdin E (2010). Dietary restriction: standing up for sirtuins. *Science* 329, 1012-1013.

IF: 28.90

Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL (2010). Spectrum and prevalence of *FP1/TMEM127* gene mutations in pheochromocytomas and paragangliomas. *JAMA-J Am Med Assoc* 304, 2611-2619.

IF: 19.53

Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjö S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG, Amati B (2010). Cdk2 suppresses cellular senescence induced by the *c-myc* oncogene. *Nat Cell Biol* 12, 54-59.

IF: 17.79

Veeck J, Roper S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M (2010). *BRCA1* CpG island hypermethylation predicts sensitivity to poly(Adenosine Diphosphate)-ribose polymerase inhibitors. *J Clin Oncol* 28, e563-e564.

IF: 14.50

Santos MA, Huen MS, Jankovic M, Chen HT, López-Contreras AJ, Klein IA, Wong N, Barbancho JL, Fernandez-Capetillo O, Nussenzweig MC, Chen J, Nussenzweig A (2010). Class switching and meiotic defects in mice lacking the E3 ubiquitin ligase RNF8. *J Exp Med* 207, 973-981.

IF: 14.07

Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL, Arias JI, Menéndez P, Benítez J, Chang-Claude J, Hein R, Wang-Gohrke S, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kosma VM, Kataja V; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer, Beesley J, Chen X, Chenevix-Trench G, Couch FJ, Olson JE, Fredericksen ZS, Wang X, Giles GG, Severi G, Baglietto L, Southey MC, Devilee P, Tollenaar RA, Seynaeve C, Garcia-Closas M, Lissowska J, Sherman ME, Bolton KL, Hall P, Czene K, Cox A, Brock IW, Elliott GC, Reed MW, Greenberg D, Anton-Culver H, Ziogas A, Humphreys M, Easton DF, Caporaso NE, Pharoah PD (2010). Association between a germline *OCA2* polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. *J Natl Cancer I* 102, 650-652.

IF: 12.27

Lauth M, Bergström A, Shimokawa T, Tostar U, Jin Q, Fendrich V, Guerra C, Barbacid M, Toftgård R (2010). DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. *Nat Struct Mol Biol* 17, 718-725.

IF: 12.27

Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U, Blasco MA, Jonkers J, Tarsounas M (2010). *BRCA2* acts as a loader to facilitate telomere replication and capping. *Nat Struct Mol Biol* 17, 1461-1469.

IF: 10.99

Thanasoula M, Escandell JM, Martinez P, Badie S, Muñoz P, Blasco MA, Tarsounas M (2010). p53 Prevents entry into mitosis with uncapped telomeres. *Curr Biol* 20, 521-526.

IF: 10.84

Reschke M, Ferby I, Stepniak E, Seitzer N, Horst D, Wagner EF, Ullrich A (2010). Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. *Hepatology* 51, 1383-1390.

IF: 10.55

Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park I-H, Wagner EF, Keller GM (2010). Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. *Blood* 115, 2769-2776.

IF: 9.53

Vogler C, Huber C, Waldmann T, Ettig R, Braun L, Izzo A, Daujat S, Chassignet I, Lopez-Contreras AJ, Fernandez-Capetillo O, Dundr M, Rippe K, Längst G, Schneider R (2010). Histone H2A C-terminus regulates chromatin dynamics, remodeling, and histone H1 binding. *PLoS Genet* 6, e1001234.

IF: 9.53

Gaudet MM, Kirchoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE; HEBON Study Collaborators, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldés T, de la Hoya M, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowitz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Toland AE, Montagna M, D'Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H; kConFab, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MI, Mai PL, Osorio A, Durán M, Andres R, Benítez J, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix-Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, Offit K, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Sinilnikova O, Barjhoux L, Giraud S, Léone M, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C, Moncoutier V, Belotti M, de Pauw A, Bressac-de-Paillerets B, Remenieras A, Byrde V, Caron O, Lenoir G, Bignon YJ, Uhrhammer N, Lasset C, Bonadona V, Hardouin A, Berthet P, Sobol H, Bourdon V, Noguchi T, Eisinger F, Coulet F, Colas C, Soubrier F, Coupier I, Peyrat JP, Fournier J, Révillion F, Vennin P, Adenis C, Rouleau E, Lidereau R, Demange L, Nogues C, Muller D, Fricker JP, Longy M, Sevenet N, Toulas C, Guimbaud R, Gladiéff L, Feillel V, Leroux D, Dreyfus H, Rebischung C, Cassini C, Faivre L, Prieur F, Ferrer SF, Fréney M, Vénat-Bouvet L, Lynch HT, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE, Hogervorst FB, Verhoef S, Verhees M, van 't Veer LJ, van Leeuwen FE, Rookus MA, Collée M, van den Ouweland AM, Jager A, Hooning MJ, Tilanus-Linthorst MM, Seynaeve C, van Asperen CJ, Wijnen JT, Vreeswijk MP, Tollenaar RA, Devilee P, Ligtenberg MJ, Hoogerbrugge N, Ausems MG, van der Luijt RB, Aalfs CM, van Os TA, Gille JJ, Waisfisz Q, Meijers-Heijboer H, Gomez-Garcia EB, van Roozendaal CE, Blok MJ, Oosterwijk JC, van der Hout AH, Mourits MJ, Vasen HF, Spurdle AB, Chenevix-Trench G (2010). Common genetic variants and modification of penetrance of *BRCA2*-associated breast cancer. *PLoS Genet* 6, e1001183.

IF: 9.43

Limongelli V, Bonomi M, Marinelli L, Gervasio FL, Cavalli A, Novellino E, Parrinello M (2010). Molecular

basis of cyclooxygenase enzymes (COXs) selective inhibition. *Proc Natl Acad Sci USA* 12, 5411-5416.

IF: 8.99

Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, Vaahtomeri K, Auchli Y, Rechsteiner H, Brunisholz RA, Viollet B, Mäkelä TP, Wallimann T, Neumann D, Krek W (2010). PKA phosphorylates and inactivates AMPK α to promote efficient lipolysis. *EMBO J* 29, 469-481.

IF: 7.54

Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowitz F, Glendon G, Ozcelik H, Andrulis IL; for the Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmal M, Melin B; for SWE-*BRCA*, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; for HEBON, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S; for EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L; for GEMO, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Fréney M, Vénat-Bouvet L; for GEMO, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; for the Breast Cancer Family Registry, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L, Agnarsson BA, Kirchoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; for kConFab, Platte R, Chenevix-Trench G, Easton DF; on behalf of CIMBA (2010). Common breast cancer susceptibility alleles and the risk of breast cancer for *BRCA1* and *BRCA2* mutation carriers: implications for risk prediction. *Cancer Res* 70, 9742-9754.

IF: 7.48

Pettifer S, Ison J, Kalas M, Thorne D, McDermott P, Jonassen I, Liaquat A, Fernández JM, Rodríguez JM; INB-Partners, Pisano DG, Blanchet C, Uludag M, Rice P, Bartaseviciute E, Rapacki K, Hekkelman M, Sand O, Stockinger H, Clegg AB, Bongcam-Rudloff E, Salzemann J, Breton V, Attwood TK, Cameron G, Vriend G (2010). The EMBRACE web service collection. *Nucleic Acids Res* 38, w683-w688.

IF: 7.33

Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, Manku H, Vyse TJ, Roncador G, Huttley GA, Goodnow CC, Vinuesa CG, Cook MC (2010). Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. *Arthritis Rheum* 62, 234-244.

IF: 7.23

Saif J, Schwarz TM, Chau DY, Henstock J, Sami P, Leicht SF, Hermann PC, Alcalá S, Mulero F, Shakesheff KM, Heeschen C, Aicher A (2010). Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. *Arterioscler Thromb Vas* 30, 1897-1904.

IF: 7.13

Frezzetti D, Menna MD, Zoppoli P, Guerra C, Ferraro A, Bello AM, Luca PD, Calabrese C, Fusco A, Ceccarelli M, Zollo M, Barbacid M, Lauro RD, Vita GD (2010). Upregulation of miR-21 by Ras *in vivo* and its role in tumor growth. *Oncogene* 30, 275-286.

IF: 6.75

Ballabio E, Chi J, Roncador G, Banham AH, Hatton CS, Lawrie CH (2010). Comparison of Choi and Hans' algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter. *Clin Cancer Res* 16, 3805-3806.

IF: 6.75

Wahlén BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E (2010). A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages. *Clin Cancer Res* 16, 637-650.

IF: 6.42

Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, Rodriguez-Justo M, Plonquet A, Rodriguez-Pinilla SM, Klapper W, Hansmann ML, Pileri SA, Isaacson PG, Stein H, Piris MA, Mason DY, Gaulard P (2010). The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. *Haematologica* 95, 432-439.

IF: 6.42

van Rijk A, Svenstrup-Poulsen T, Jones M, Cabeçadas J, Cigudosa JC, Leoncini L, Mottok A, Bergman CC, Poulidou E, Dutoit SH, van Krieken HJ (2010). Double staining CISH as a useful alternative to split-signal FISH in lymphoma diagnostics. *Haematologica* 95, 247-252.

IF: 6.42

Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T (2010). The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying *c-MYC* translocated lymphomas. *Haematologica* 95, 2056-2062.

IF: 6.20

Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valimäki M, Preuss SF, Hasse-Lazar K, Waligorski D, Robledo M, Januszewicz A, Eng C, Neumann HP (2010). Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. *J Clin Endocrinol Metab* 95, 308-313.

IF: 6.14

Gurden MD, Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, Spielmann HP, Malumbres M, Wolthuis RM, Cleveland DW, Taylor SS (2010). Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F. *J Cell Sci* 123, 321-330.

IF: 6.00

Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X (2010). Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. *Cancer Prev Res* 3, 1235-1245.

IF: 5.98

Katiyar S, Casimiro MC, Dettin L, Ju X, Wagner EF, Tanaka H, Pestell RG (2010). C-jun inhibits mammary apoptosis *in vivo*. *Mol Biol Cell* 21, 4264-4274.

IF: 5.67

Singh S, Vinson C, Gurley CM, Nolen GT, Beggs ML, Nagarajan R, Wagner EF, Parham DM, Peterson CA (2010). Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. *Am J Pathol* 177, 2055-2066.

IF: 5.65

Takada Y, Ray N, Ikeda E, Kawaguchi T, Kuwahara M, Wagner EF, Matsuo K (2010). Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF- κ B. *J Immunol* 184, 1014-1021.

IF: 5.65

Charni S, de Bettignies G, Rathore MG, Aguiló JJ, van den Elsen PJ, Haouzi D, Hipskind RA, Enriquez JA, Sanchez-Beato M, Pardo J, Anel A, Villalba M (2010). Oxidative phosphorylation induces *De Novo* expression of the MHC Class I in tumor cells through the ERK5 Pathway. *J Immunol* 185, 3498-3503.

IF: 5.33

Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benitez J, Arias Perez JJ, Zamora MP, Malats N, Dos Santos Silva I, Gibson LJ, Fletcher O, Johnson N, Anton-Culver H, Ziogas A, Figueroa J, Brinton L, Sherman ME, Lissowska J, Hopper JL, Dite GS, Apicella C, Southey MC, Sigurdson AJ, Linet MS, Schonfeld SJ, Freedman DM, Mannermaa A, Kosma VM, Kataja V, Auvinen P, Andrulis IL, Glendon G, Knight JA, Weerasooriya N, Cox A, Reed MW, Cross SS, Dunning AM, Ahmed S, Shah M, Brauch H, Ko YD, Bruning T, Genica Network T, Lambrechts D, Reumers J, Smeets A, Wang-Gohrke S, Hall P, Czene K, Liu J, Irwanto AK, Chenevix-Trench G, Holland H, Kconfab Investigators T, Aocs Investigators T, Giles GG, Severi G, Baglietto L, Bojesen SE, Nordestgaard BG, Flygler H, John EM, West DW, Whittemore AS, Vachon C, Olson JE, Fredericksen Z, Kosel M, Hein R, Vrieling A, Flesch-Janys D, Heinz J, Beckmann M, Heusinger K, Ekici AB, Haeberle L, Easton DF, Humphreys MK, Morrison J, Pharoah PD, Garcia-Closas M, Goode EL, Chang-Claude J (2010). Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. *Breast Cancer Res* 12, R110.

IF: 4.79

Galvan A, Falvella FS, Frullanti E, Spinola M, Incarbone M, Nosotti M, Santambrogio L, Conti B, Pastorino U, Gonzalez-Neira A, Dragani TA (2010). Genome-wide association study in discordant sibships identifies multiple inherited susceptibility alleles linked to lung cancer. *Carcinogenesis* 31, 462-465.

IF: 4.70

Keegan TH, Milne RL, Andrulis IL, Chang ET, Sangaramoorthy M, Phillips KA, Giles GG, Goodwin PJ, Apicella C, Hopper JL, Whittemore AS, John EM (2010). Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry. *Breast Cancer Res Treat* 123, 531-542.

IF: 4.70

Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS (2010). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. *Breast Cancer Res Treat* 121, 575-589.

IF: 4.70

Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG (2010). Co-amplification of *CCND1* and *EMSY* is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. *Breast Cancer Res Treat* 121, 347-354.

IF: 4.60

Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F (2010). Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. *Br J Haematol* 151, 221-231.

IF: 4.60

Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, Chigrinova E, Zucca E, Favera RD, Gaidano G, Kwee I, Bertoni F (2010). Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. *Br J Haematol* 149, 569-577.

IF: 4.60

Rinaldi A, Forconi F, Arcaini L, Mian M, Sozzi E, Zibellini S, Baldini L, Franceschetti S, Gaidano G, Marasca R, Mollejo M, Piris MA, Tucci A, Facchetti F, Bhagat G, Favera RD, Rancoita PM, Zucca E, Kwee I, Bertoni F (2010). Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. *Br J Haematol* 151, 435-439.

IF: 4.60

Capello D, Scandurra M, Poretti G, Rancoita PM, Mian M, Gloghini A, Deambrogi C, Martini M, Rossi D, Greiner TC, Chan WC, Ponzoni M, Moreno SM, Piris MA, Canzonieri V, Spina M, Tirelli U, Inghirami G, Rinaldi A, Zucca E, Favera RD, Cavalli F, Larocca LM, Kwee I, Carbone A, Gaidano G, Bertoni F (2010). Genome wide DNA-profiling of HIV-related B-cell lymphomas. *Br J Haematol* 148, 245-255.

IF: 4.60

Campbell AJ, Lyne L, Brown PJ, Launchbury RJ, Bignone P, Chi J, Roncador G, Lawrie CH, Gatter KC, Kusec R, Banham AH (2010). Aberrant expression of the neuronal transcription factor *FOXP2* in neoplastic plasma cells. *Br J Haematol* 149, 221-230.

IF: 4.52

Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M (2010). Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. *Hum Genet* 127, 1-17.

IF: 4.35

Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrusis IL, Southey MC, McCredie MR, Giles GG, Miron A, Phipps AI, West DW, Hopper JL (2010). Increased cancer risks for relatives of very early-onset breast cancer cases with and without *BRCA1* and *BRCA2* mutations. *Br J Cancer* 103, 1103-1108.

IF: 4.35

Lynch CJ, Shah ZH, Allison SJ, Ahmed SU, Ford J, Warnock LJ, Li H, Serrano M, Milner J (2010). SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. *PLoS One* 5, e13502.

IF: 4.35

Bonomi M, Barducci A, Gervasio FL, Parrinello M (2010). Multiple routes and milestones in the folding of HIV-1 protease monomer. *PLoS One* 5, e13208.

IF: 4.35

Bartlett JD, Dobeck JM, Tye CE, Perez-Moreno M, Stokes N, Reynolds AB, Fuchs E, Skobe Z (2010). Targeted p120-catenin ablation disrupts dental enamel development. *PLoS One* 5, e12703.

IF: 4.34

Hyter S, Bajaj G, Liang X, Barbacid M, Ganguli-Indra G, Indra AK (2010). Loss of nuclear receptor RXRa in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. *Pigment Cell Melanoma Res* 23, 635-648.

IF: 4.31

Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Waltes R, Bremer M, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Humphreys K, Liu J, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G; kConFab Investigators; AOCs Group, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U; GENICA Consortium, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benítez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J; Breast Cancer Association Consortium (2010). Missense variants in *ATM* in 26,101 breast cancer cases and 29,842 controls. *Cancer Epidemiol Biomarkers Prev* 19, 2143-2151.

IF: 4.31

Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D,

Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological Study of Familial Breast Cancer (EMBRACE), McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab), Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; Swedish Breast Cancer Study, Sweden (SWE-BRCA), van der Luijt RB, van Os TA, van Leeuwen FE; Hereditary Breast and Ovarian cancer group Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrusis IL, Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (2010). Association of the variants *CASP8* D302H and *CASP10* V410I with breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 19, 2859-2868.

IF: 4.28

Eric Z, Ploekinger U, Cascon A, Hoffmann MM, von Duecker L, Winter A, Kammel G, Bacher J, Sullivan M, Isermann B, Fischer L, Raffel A, Knoefel WT, Schott M, Baumann T, Schaefer O, Keck T, Baum RP, Milos I, Muresan M, Peczkowska M, Januszewicz A, Cupisti K, Tönjes A, Fasshauer M, Langrehr J, von Wussow P, Agaimy A, Schlimok G, Lamberts R, Wiech T, Schmid KW, Weber A, Nunez M, Robledo M, Eng C, Neumann HP; VHL-ICT Consortium; German NET Registry (2010). Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. *Endocr-Relat Cancer* 17, 875-883.

IF: 3.08

Servais AC, Rousseau A, Fillet M, Lomsadze K, Salgado A, Crommen J, Chankvetadze B (2010). Separation of propranolol enantiomers by CE using sulfated beta-CD derivatives in aqueous and non-aqueous electrolytes: comparative CE and NMR study. *Electrophoresis* 31, 1467-1474.

IF: 2.96

Churchill HR, Roncador G, Warnke RA, Natkunam Y (2010). Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. *Hum Pathol* 41, 1726-1734.

IF: 2.82

Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M,

Volpi D, Vulpetti A, Ciomei M (2010). Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. *Bioorgan Med Chem* 18, 1844-1853.

IF: 2.53

Goebell PJ, Morente MM (2010). New concepts of biobanks--strategic chance for uro-oncology. *Urol Oncol* 28, 449-457.

IF: 2.53

Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB (2010). Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol* 28, 441-448.

IF: 2.53

Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N (2010). Statistical consideration for clinical biomarker research in bladder cancer. *Urol Oncol* 28, 389-400.

IF: 2.40

Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubert S, Roberts AE, Gelb BD,

Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T (2010). Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: from bedside to bench and back. *Am J Med Genet A* 152A, 4-24.

IF: 2.30

Bevilacqua G, Bosman F, Dassel T, Höfler H, Janin A, Langer R, Larsimont D, Morente MM, Riegman P, Schirmacher P, Stanta G, Zatloukal K, Caboux E, Hainaut P (2010). The role of the pathologist in tissue banking: European Consensus Expert Group Report. *Virchows Arch* 456, 449-454.

IF: 1.87

Scandurra M, Rossi D, Deambrogi C, Rancoita PM, Chigrinova E, Mian M, Cerri M, Rasi S, Sozzi E, Forconi F, Ponzoni M, Moreno SM, Piris MA, Inghirami G, Zucca E, Gattei V, Rinaldi A, Kwee I, Gaidano G, Bertoni F (2010). Genomic profiling of Richter's syndrome: recurrent lesions and differences with *de novo* diffuse large B-cell lymphomas. *Hematol Oncol* 28, 62-67.

IF: 1.70

Bidoia C, Mazzorana M, Pagano MA, Arrigoni G, Meggio F, Pinna LA, Bertazzoni U (2010). The

pleiotropic protein kinase CK2 phosphorylates HTLV-1 Tax protein *in vitro*, targeting its PDZ-binding motif. *Virus Genes* 41, 149-157.

IF: 1.35

Morley KI, Milne RL, Giles GG, Southey MC, Apicella C, Hoppe JL, Phillips KA (2010). Socio-economic status and survival from breast cancer for young, Australian, urban women. *Aust Nz J Publ Heal* 34, 200-205.

IF: 0.30

Macdonald RJ, Swift GH, Real FX (2010). Transcriptional control of acinar development and homeostasis. *Prog Mol Biol Transl* 97, 1-40.

The following articles were published in peer-reviewed journals that have not been allocated an impact factor

Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A (2010). Recommendations for biomarker identification and qualification in clinical proteomics. *Sci Transl Med* 2, 46ps42.

Blagosklonny MV, Campisi J, Sinclair DA, Bartke A, Blasco MA, Bonner WM, Bohr VA, Brosh RM Jr, Brunet A, Depinho RA, Donehower LA, Finch CE, Finkel T, Gorospe M, Gudkov AV, Hall MN, Hekimi S, Helfand SL, Karlseder J, Kenyon C, Kroemer G, Longo V, Nussenzweig A, Osiewacz HD, Peeper DS, Rando TA, Rudolph KL, Sassone-Corsi P, Serrano M, Sharpless NE, Skulachev VP, Tilly JL, Tower J, Verdin E, Vijg J (2010). Impact papers on aging in 2009. *Aging (Albany)* 2, 111-121.

Katayama T, Arakawa K, Nakao M, Ono K, Aoki-Kinoshita KF, Yamamoto Y, Yamaguchi A, Kawashima S, Chun HW, Aerts J, Aranda B, Barboza LH, Bonnal RJ, Bruskiwicz R, Bryne JC, Fernández JM, Funahashi A, Gordon PM, Goto N, Groscurth A, Gutteridge A, Holland R, Kano Y, Kawas EA, Kerhornou A, Kibukawa E, Kinjo AR, Kuhn M, Lapp H, Lehvaslaiho H, Nakamura H, Nakamura Y, Nishizawa T, Nobata C, Noguchi T, Oinn TM, Okamoto S, Owen S, Pafilis E, Pocock M, Prins P, Ranzinger R, Reisinger F, Salwinski L, Schreiber M, Senger M, Shigemoto Y, Standley DM, Sugawara H, Tashiro T, Trelles O, Vos RA, Wilkinson MD, York W, Zmasek CM, Asai K, Takagi T (2010). The DBCLS BioHackathon: standardization and interoperability for bioinformatics web services and workflows. The DBCLS BioHackathon Consortium. *J Biomed Semantics* 1, 8.

Hainaut P, Caboux E, Bevilacqua G, Bosman F, Dassel T, Hoefler H, Janin A, Langer R, Larsimont D, Morente MM, Riegman P, Schirmacher P, Stanta G, Zatloukal K (2010). Pathology as the cornerstone of human tissue banking: European Consensus Expert Group Report. *Biopreservation & Biobanking* 7, 157-160.

Barbakadze V, Gogilashvili L, Amiranashvili L, Merlani M, Mulkijanyan K, Churadze M, Salgado A, Chankvetadze B (2010). Poly[3-(3,4-dihydroxyphenyl) glyceric acid] from *Anchusa italica* roots. *Nat Prod Commun* 5, 1091-1095.

Collaborations with Spanish institutions

IF: 25.28

Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G, Yamamoto H, Schwartz S Jr, Esteller M (2010). A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. *Cancer Cell* 18, 303-315.

IF: 12.53

González-Navarro H, Abu Nabah YN, Vinué A, Andrés-Manzano MJ, Collado M, Serrano M, Andrés V (2010). p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. *J Am Coll Cardiol* 55, 2258-2268.

IF: 12.30

Rodríguez-Santiago B, Malats N, Rothman N, Armengol L, García-Closas M, Kogevinas M, Villa O, Hutchinson A, Earl J, Marenne G, Jacobs K, Rico D, Tardón A, Carrato A, Thomas G, Valencia A, Silverman D, Real FX, Chanock SJ, Pérez-Jurado LA (2010). Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. *Am J Hum Genet* 87, 129-138.

IF: 10.55

Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Włodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F (2010). Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-Cell Lymphoma Group. *Blood* 116, 1479-1488.

IF: 9.43

Guerrero AA, Gamero MC, Trachana V, Fütterer A, Pacios-Bras C, Díaz-Concha NP, Cigudosa JC, Martínez-A C, van Wely KH (2010). Centromere-localized breaks indicate the generation of DNA damage by the mitotic spindle. *Proc Natl Acad Sci USA* 107, 4159-4164.

IF: 9.43

Kumar A, Fernandez-Capetillo O, Carrera AC (2010). Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair. *Proc Natl Acad Sci USA* 107, 7491-7496.

IF: 9.43

Calvanese V, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N, López-Nieva P, Horrillo A, Hmadcha A, Soria B, Piazzolla D, Herranz D, Serrano M, Mato JM, Andrews PW, López-Larrea C, Esteller M, Fraga MF (2010). Sirtuin 1 regulation of developmental genes during differentiation of stem cells. *Proc Natl Acad Sci USA* 107, 13736-13741.

IF: 7.54

Borràs E, Pineda M, Blanco I, Jewett EM, Wang F, Teulé A, Caldés T, Urioste M, Martínez-Bouzas C, Brunet J, Balmaña J, Torres A, Ramón y Cajal T, Sanz J, Pérez-Cabornero L, Castellví-Bel S, Alonso A, Lanás A, González S, Moreno V, Gruber SB, Rosenberg NA, Mukherjee B, Lázaro C, Capellá G (2010). *MLH1* founder mutations with moderate penetrance in Spanish Lynch syndrome families. *Cancer Res* 70, 7379-7391.

IF: 7.54

Fernández V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E (2010). Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. *Cancer Res* 70, 1408-1418.

IF: 7.13

Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA (2010). Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. *Oncogene* 29, 6071-6083.

IF: 6.47

Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M. (2010). Gene amplification of the transcription factor *DP1* and *CTNND1* in human lung cancer. *J Pathol* 222, 89-98.

IF: 6.25

Mavillard F, Hidalgo J, Megias D, Levitsky KL, Velasco A (2010). PKA-mediated Golgi remodeling during cAMP signal transmission. *Traffic* 11, 90-109.

IF: 6.19

Cantor KP, Villanueva CM, Silverman D, Figueroa JD, Real FX, Garcia-Closas M, Malats N, Chanock S, Yeager M, Tardon A, Garcia-Closas R, Serra C, Carrato A, Castaño-Vinyals G, Samanic C, Rothman N, Kogevinas M (2010). Polymorphisms in *GSTT1*, *GSTZ1*, and *CYP2E1*, disinfection byproducts, and risk of bladder cancer in Spain. *Environ Health Persp* 118, 1545-1550.

IF: 6.14

Carilla-Latorre S, Gallardo ME, Annesley SJ, Calvo-Garrido J, Graña O, Accari SL, Smith PK, Valencia A, Garesse R, Fisher PR, Escalante R (2010). MidA is a putative methyltransferase that is required for mitochondrial complex I function. *J Cell Sci* 123, 1674-1683.

IF: 6.06

Martín-Villar E, Fernández-Muñoz B, Parsons M, Yurrita MM, Megias D, Pérez-Gómez E, Jones GE, Quintanilla M (2010). Podoplanin associates with CD44 to promote directional cell migration. *Mol Biol Cell* 21, 4387-4399.

IF: 5.54

Sánchez-Schmidt JM, Salgado R, Servitje O, Gallardo F, Ortiz-Romero PL, Karpova MB, Zipser MC, García-Muret MP, Estrach T, Rodríguez-Pinilla SM, Climent F, Suela J, Ferreira BI, Cigudosa JC, Salido M, Barranco C, Serrano S, Dummer R, Solé F, Pujol RM, Espinet B (2010). Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide ArrayCGH approach. *J Invest Dermatol* 131, 269-271.

IF: 5.54

Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, Zipser MC, Muniesa C, García-Muret MP, Estrach T, Salido M, Sánchez-Schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Solé F, Pujol RM, Espinet B (2010). Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. *J Invest Dermatol* 130, 1126-1135.

IF: 5.33

Marfil V, Moya M, Pierreux CE, Castell JV, Lemaigre FP, Real FX, Bort R (2010). Interaction between Hhex and SOX13 modulates Wnt/TCF activity. *J Biol Chem* 285, 5726-5737.

IF: 5.33

Sánchez R, Pantoja-Uceda D, Prieto J, Diercks T, Marcaida MJ, Montoya G, Campos-Olivas R, Blanco FJ (2010). Solution structure of human growth arrest and DNA damage 45 α (Gadd45 α) and its interactions with proliferating cell nuclear antigen (PCNA) and Aurora A kinase. *J Biol Chem* 285, 22196-22201.

IF: 4.93

Calle ML, Urrea V, Malats N, Van Steen K (2010). mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. *Bioinformatics* 26, 2198-2199.

IF: 4.79

Santibanez JF, Pérez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, Malumbres M, Vary CP, Quintanilla M, Bernabéu C (2010). The TGF- β co-receptor endoglin modulates the expression and transforming potential of H-Ras. *Carcinogenesis* 31, 2145-2154.

IF: 4.60

Martín-Sánchez E, Sánchez-Beato M, Rodríguez ME, Sánchez-Espirióñ B, Gómez-Abad C, Bischoff JR,

Piris MA, García-Orad A, García JF (2010). HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. *Br J Haematol* 152, 352-356.

IF: 4.09

Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S (2010). miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. *Cell Cycle* 9, 3277-3285.

IF: 3.87

Palacios A, Moreno A, Oliveira BL, Rivera T, Prieto J, García P, Fernández-Fernández MR, Bernadó P, Palmero I, Blanco FJ (2010). The dimeric structure and the bivalent recognition of H3K4me3 by the tumor suppressor ING4 suggests a mechanism for enhanced targeting of the HBO1 complex to chromatin. *J Mol Biol* 396, 1117-1127.

IF: 3.76

Ferreiro I, Joaquin M, Islam A, Gomez-Lopez G, Barragan M, Lombardía L, Domínguez O, Pisano DG, Lopez-Bigas N, Nebreda AR, Posas F (2010). Whole genome analysis of p38 SAPK-mediated gene expression upon stress. *BMC Genomics* 11, 144.

IF: 3.59

García S, Bernad A, Martín MC, Cigudosa JC, García-Castro J, de la Fuente R (2010). Pitfalls in spontaneous *in vitro* transformation of human mesenchymal stem cells. *Exp Cell Res* 316, 648-650.

IF: 3.27

Ramos-Lima FJ, Moneo V, Quiroga AG, Carnero A, Navarro-Ranninger C (2010). The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. *Eur J Med Chem* 45, 134-141.

IF: 3.25

Gasull M, Porta M, Pumarega J, Vioque J, Bosch de Basea M, Puigdomènech E, Morales E, Grimalt JO, Malats N (2010). The relative influence of diet and serum concentrations of organochlorine compounds on K-ras mutations in exocrine pancreatic cancer. *Chemosphere* 79, 686-697.

IF: 3.20

Prado N, Cañamero M, Villalba M, Rodríguez R, Batanero E. (2010). Bystander suppression to unrelated allergen sensitization through intranasal administration of tolerogenic exosomes in mouse. *Mol Immunol* 47, 2148-2151.

IF: 2.93

Rivera J, Megías D, Bravo J (2010). Sorting nexin 6 interacts with breast cancer metastasis suppressor-1 and promotes transcriptional repression. *J Cell Biochem* 111, 1464-1472.

IF: 2.60

Romero-Beviar M, Martínez-Rodríguez S, Prieto J, Goormaghtigh E, Ariz U, Martínez-Chantar Mde L, Gómez J, Neira JL (2010). The N-terminal domain of the enzyme I is a monomeric well-folded protein with a low conformational stability and residual

structure in the unfolded state. *Protein Eng Des Sel* 23, 729-742.

IF: 2.40

Pié J, Gil-Rodríguez MC, Ciero M, López-Viñas E, Ribate MP, Arnedo M, Deardorff MA, Puisac B, Legarreta J, de Karam JC, Rubio E, Bueno I, Baldellou A, Calvo MT, Casals N, Olivares JL, Losada A, Hegardt FG, Krantz ID, Gómez-Puertas P, Ramos FJ (2010). Mutations and variants in the cohesion factor genes *NIPBL*, *SMC1A*, and *SMC3* in a cohort of 30 unrelated patients with Cornelia de Lange syndrome. *Am J Med Genet A* 152, 924-929.

IF: 2.30

Lopez-Beltran A, Ordóñez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Muñoz E, Cheng L, Montironi R, de Alava E (2010). Cyclin D3 gene amplification in bladder carcinoma *in situ*. *Virchows Arch* 457, 555-561.

IF: 1.49

Garrido-Ruiz MC, Rodríguez-Pinilla SM, Pérez-Gómez B, Rodríguez-Peralto JL (2010). WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. *J Cutan Pathol* 37, 542-548.

IF: 1.15

Quintela-Fandino M, González-Martín A, Colomer R (2010). Targeting cytoskeleton reorganisation as antimetastatic treatment. *Clin Transl Oncol* 12, 662-669.

The following article was published in peer-reviewed journals that have not been allocated an impact factor

Glez-Peña D, Reboiro-Jato M, Domínguez R, Gómez-López G, Pisano DG, Fdez-Riverola F (2010). PathJam: a new service for integrating biological pathway information. *J Integr Bioinform* 7, 147.

Patents

Tormo D, Soengas MS (2010). Procedure for the identification of dsRNA inducers and their use as anticancer agents (OEPM-04/07/2009). PCT European Patent Application P20100595993. Licensed to *Bioncotech Therapeutics*.

Real FX, Méndez-Pértuz M, Muñoz A (2010). *Compuestos para el tratamiento del cáncer*. Spanish Patent Application P201030688.

Sánchez-Carbayo M (2010). Method for the diagnosis and tumor stratification in bladder cancer. Spanish Patent Application P201030187.

Pastor Fernandez J, Martínez González S, Oyarzabal Santamaría J (2010). Preparation of imidazopyrazines for use as kinase inhibitors. PCT Int Appl WO 2010119264 A1 20101021.

Pastor Fernández J, Kurz G, Martínez González S (2010). Preparation of imidazo[2,1-b][1,3,4]thiadiazole derivatives as P13-K inhibitors for treating cancer and other diseases. PCT Int Appl WO 2010112874 A1 20101007.

Marcaida López MJ, Prieto Lugo FJ, Montoya G, (2010). The crystal structure of I-Dmol in complex with its target DNA. Improved chimeric meganucleases and uses thereof. PCT Int Appl WO2010001189.

Martínez JL, Abengozar MA (2010). Antibody against ephrin B2 and its uses (OEPM-21/09/2010). Spanish Patent Application P201031402.